195 related articles for article (PubMed ID: 19247496)
1. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice.
Gogishvili T; Langenhorst D; Lühder F; Elias F; Elflein K; Dennehy KM; Gold R; Hünig T
PLoS One; 2009; 4(2):e4643. PubMed ID: 19247496
[TBL] [Abstract][Full Text] [Related]
2. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T
Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661
[TBL] [Abstract][Full Text] [Related]
3. CD28 superagonist-induced regulatory T cell expansion ameliorates mesangioproliferative glomerulonephritis in rats.
Miyasato K; Takabatake Y; Kaimori J; Kimura T; Kitamura H; Kawachi H; Li XK; Hünig T; Takahara S; Rakugi H; Isaka Y
Clin Exp Nephrol; 2011 Feb; 15(1):50-7. PubMed ID: 21076989
[TBL] [Abstract][Full Text] [Related]
4. CD28 signals the differential control of regulatory T cells and effector T cells.
Mikami N; Sakaguchi S
Eur J Immunol; 2014 Apr; 44(4):955-7. PubMed ID: 24652756
[TBL] [Abstract][Full Text] [Related]
5. In vivo activation of Treg cells with a CD28 superagonist prevents and ameliorates chronic destructive arthritis in mice.
Win SJ; Kühl AA; Sparwasser T; Hünig T; Kamradt T
Eur J Immunol; 2016 May; 46(5):1193-202. PubMed ID: 26711629
[TBL] [Abstract][Full Text] [Related]
6. Superagonistic CD28 Protects against Renal Ischemic Injury by Expansion of Regulatory T-Cell.
Liang Y; Li Y; Kuang Q; Ding X; Wei Z; Fang Y
Am J Nephrol; 2017; 45(5):389-399. PubMed ID: 28355607
[TBL] [Abstract][Full Text] [Related]
7. Self-Recognition Sensitizes Mouse and Human Regulatory T Cells to Low-Dose CD28 Superagonist Stimulation.
Langenhorst D; Tabares P; Gulde T; Becklund BR; Berr S; Surh CD; Beyersdorf N; Hünig T
Front Immunol; 2017; 8():1985. PubMed ID: 29441059
[TBL] [Abstract][Full Text] [Related]
8. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.
Thaventhiran T; Alhumeed N; Yeang HX; Sethu S; Downey JS; Alghanem AF; Olayanju A; Smith EL; Cross MJ; Webb SD; Williams DP; Bristow A; Ball C; Stebbings R; Sathish JG
MAbs; 2014; 6(5):1290-9. PubMed ID: 25517314
[TBL] [Abstract][Full Text] [Related]
9. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies.
Waibler Z; Sender LY; Merten C; Hartig R; Kliche S; Gunzer M; Reichardt P; Kalinke U; Schraven B
PLoS One; 2008 Mar; 3(3):e1708. PubMed ID: 18320029
[TBL] [Abstract][Full Text] [Related]
10. Single CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells.
He X; Smeets RL; van Rijssen E; Boots AM; Joosten I; Koenen HJ
Sci Rep; 2017 Feb; 7():43003. PubMed ID: 28223693
[TBL] [Abstract][Full Text] [Related]
11. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
[TBL] [Abstract][Full Text] [Related]
12. Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice.
Na SY; Mracsko E; Liesz A; Hünig T; Veltkamp R
Stroke; 2015 Jan; 46(1):212-20. PubMed ID: 25378432
[TBL] [Abstract][Full Text] [Related]
13. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis.
Tyrsin D; Chuvpilo S; Matskevich A; Nemenov D; Römer PS; Tabares P; Hünig T
Clin Exp Rheumatol; 2016; 34(4 Suppl 98):45-8. PubMed ID: 27586803
[TBL] [Abstract][Full Text] [Related]
14. Selective expansion of memory CD4(+) T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells.
Singh M; Basu S; Camell C; Couturier J; Nudelman RJ; Medina MA; Rodgers JR; Lewis DE
Eur J Immunol; 2008 Jun; 38(6):1522-32. PubMed ID: 18446791
[TBL] [Abstract][Full Text] [Related]
15. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.
Hünig T
FEBS J; 2016 Sep; 283(18):3325-34. PubMed ID: 27191544
[TBL] [Abstract][Full Text] [Related]
16. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.
Poirier N; Mary C; Le Bas-Bernardet S; Daguin V; Belarif L; Chevalier M; Hervouet J; Minault D; Ville S; Charpy V; Blancho G; Vanhove B
MAbs; 2014; 6(3):697-707. PubMed ID: 24598534
[TBL] [Abstract][Full Text] [Related]
17. Sequential induction of effector function, tissue migration and cell death during polyclonal activation of mouse regulatory T-cells.
Langenhorst D; Gogishvili T; Ribechini E; Kneitz S; McPherson K; Lutz MB; Hünig T
PLoS One; 2012; 7(11):e50080. PubMed ID: 23226238
[TBL] [Abstract][Full Text] [Related]
18. Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice.
Badr M; McFleder RL; Wu J; Knorr S; Koprich JB; Hünig T; Brotchie JM; Volkmann J; Lutz MB; Ip CW
J Neuroinflammation; 2022 Dec; 19(1):319. PubMed ID: 36587195
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
[TBL] [Abstract][Full Text] [Related]
20. CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program.
Thaventhiran T; Wong W; Alghanem AF; Alhumeed N; Aljasir MA; Ramsey S; Sethu S; Yeang HXA; Chadwick AE; Cross M; Webb SD; Djouhri L; Ball C; Stebbings R; Sathish JG
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):60-69. PubMed ID: 31009338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
